Activity Overview
This educational activity is an archive of the live presentation held on May 29, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists,
pathologists, advanced practice providers, and other health care providers
involved in the management of extrapulmonary neuroendocrine carcinomas (EP-NECs).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess evolving strategies to accurately diagnose EP-NECs and the emerging role of novel biomarkers, including DLL3, in improving patient selection for targeted therapies
- Evaluate key efficacy and safety data from recent and ongoing clinical trials investigating DLL3-targeted therapies and other emerging treatment strategies for EP-NECs
- Integrate biomarker testing results and emerging clinical evidence into personalized treatment plans for patients with advanced EP-NECs
- Recognize, monitor, and manage treatment-related toxicities associated with emerging DLL3-directed therapies in patients with EP-NECs
Aman Chauhan, MD, MBBS
Associate Professor of Clinical Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: BI, Curium, Ipsen, Novartis, Sanofi, TerSera; Ownership interests in publicly traded companies: IMTX, KURA
Jonathan Strosberg, MD
Professor, Department of Gastrointestinal Oncology
Moffitt Cancer Center
Tampa, FL
Disclosures: Advisor, Consultant, Fee for Service Recipient: Boehringer Ingelheim, Curium, Exelixis, Merck, Sanofi; Grant/Research Funding: Exelixis, ITM, Rayze-Bio, Sanofi
Sylvia L. Asa, MD, PhD
Professor of Pathology
Case Western Reserve University
Pathologist
University Hospitals Cleveland
Cleveland, OH
Disclosures: Advisor, Consultant, Fee for Service Recipient: Boehringer Ingelheim, Leica Biosystems
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.